Preferred Label : Lanraplenib;
NCIt definition : An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating
and antineoplastic activities. Upon oral administration, lanraplenib binds to and
inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which
leads to the inhibition of B-cell activation, and prevents tumor cell activation,
migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated
tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed
in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.;
UNII : A6U64OU57E;
InChIKey : XCIGZBVOUQVIPI-UHFFFAOYSA-N;
CAS number : 1800046-95-0;
Molecule name : GS-9876;
NCI Metathesaurus CUI : CL1411873;
Origin ID : C174607;
UMLS CUI : C5139726;
Semantic type(s)
- concept_is_in_subset
